StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Hold

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

ORMP stock opened at $2.34 on Monday. Oramed Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $3.67. The company has a market capitalization of $95.40 million, a price-to-earnings ratio of 4.59 and a beta of 1.77. The business’s 50 day moving average price is $2.38 and its two-hundred day moving average price is $2.38.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.21. Sell-side analysts forecast that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in Oramed Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Virtu Financial LLC purchased a new stake in shares of Oramed Pharmaceuticals in the first quarter worth $68,000. Dimensional Fund Advisors LP increased its holdings in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Oramed Pharmaceuticals in the 3rd quarter worth about $272,000. Finally, Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.